This prospective study aimed to evaluate the clinical impact of FLCs in HD patients, analyzing their relations with other biomarkers of inflammation and immunity status, such as C-reactive protein (CRP), serum HMGB1, and main lymphocyte subsets. Here, HMGB1 is linked to Huntington disease.